Border Reopening and Covid-19 Preparation: Impact on Breast Cancer Healthcare Provision From a West Australian Perspective

England, Thomas

doi:10.26226/m.631a4b817e215f5e7f3857b0

2022

DOI: 10.26226/m.631a4b817e215f5e7f3857b0

|View full text |Cite

Preprint

Border Reopening and Covid-19 Preparation: Impact on Breast Cancer Healthcare Provision From a West Australian Perspective

Thomas England¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Is staging breast magnetic resonance imaging for invasive lobular carcinoma worthwhile?

Melvin,

Lim,

Jacques

et al. 2024

ANZ Journal of Surgery

View full text Add to dashboard Cite

BackgroundInvasive lobular carcinoma (ILC) is challenging to stage accurately using mammography (MG) and ultrasound (US) with undiagnosed ipsilateral and contralateral cancer resulting in poor patient outcomes including return to surgery. Our institution employs routine staging breast MRI in ILC for this reason. However, increased time for further imaging/biopsies contributes to patient anxiety and potentially delays definite management. We aimed to quantify the frequency of staging MRI‐detected additional lesions requiring biopsy or follow‐up, the added cancer detection rate and MRI prompted change in surgical management.MethodsAn observational study on staging breast MRI for newly diagnosed ILC at a tertiary Western Australian hospital from January 2019 to August 2022. Standardized 3T MRI protocol was performed, double read by unblinded fellowship‐trained radiologists. Histopathology from biopsy, surgery, or first annual surveillance was the reference standard for additional MRI‐detected lesions.ResultsOne hundred ten MRI studies demonstrated 49 (45%) patients had at least one additional clinically significant MRI‐detected lesion. Thirty‐one patients had an additional ipsilateral lesion detected, of which 18 (58%) proved malignant; 14 (45%) multifocal and 4 (13%) multicentric ILC. Additional work‐up of MRI‐detected lesions averaged a 9‐day delay to definitive surgery compared to patients with a negative or definitively benign MRI. MRI changed surgical planning in 11 of 110 cases from breast conservation surgery (BCS) to mastectomy and there were two contralateral cancers diagnosed. BCS reoperation rate was 11%.ConclusionStaging MRI for ILC identifies clinically significant lesions in nearly half of patients, predominantly ipsilateral multifocal disease, without significant delay to definitive surgery.

show abstract

Is staging breast magnetic resonance imaging for invasive lobular carcinoma worthwhile?

Melvin,

Lim,

Jacques

et al. 2024

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Border Reopening and Covid-19 Preparation: Impact on Breast Cancer Healthcare Provision From a West Australian Perspective

Cited by 1 publication

References 0 publications

Is staging breast magnetic resonance imaging for invasive lobular carcinoma worthwhile?

Is staging breast magnetic resonance imaging for invasive lobular carcinoma worthwhile?

Contact Info

Product

Resources

About